3.
Tumor response and PFS in G719X/S768I/L861Q subtypes
| EGFR mutation | n (%) | PFS [median (range)] (month) | |
| DCR | ORR | ||
| EGFR, epidermal growth factor receptor; DCR, disease control rate; ORR, objective response rate; PFS, progression-free survival. | |||
| G719X (N=22) | 20 (90.9) | 5 (22.7) | 7.6 (4.9−10.4) |
| G719X (n=14) | |||
| G719X + S768I (n=5) | |||
| G719X + L858R (n=2) | |||
| G719X + E709A (n=1) | |||
| S768I (N=11) | 10 (90.9) | 3 (27.3) | 8.0 (4.3−11.8) |
| S768I (n=4) | |||
| S768I + G719X (n=5) | |||
| S768I + L858R (n=2) | |||
| L861Q (N=5) | 5 (100) | 0 (0) | 5.7 (1.6−9.8) |
| L861Q (n=4) | |||
| L861Q + L858R (n=1) | |||